Scientists discover why Ozempic and Wegovy weight loss eventually plateaus
New research from the NIH has revealed insights into why weight loss from GLP-1 drugs like Ozempic and Wegovy plateaus over time. The study found that the effects of semaglutide on appetite-controlling brain cells vary among individuals and can diminish as neurons adapt. Researchers also identified potential methods to extend the drug's effectiveness, which may help patients overcome weight loss plateaus.
- ▪NIH researchers discovered that semaglutide affects brain cells differently, leading to varied weight loss responses.
- ▪The study showed that some neurons maintain elevated cAMP levels longer than others when treated with semaglutide.
- ▪Using the drug roflumilast, scientists were able to prolong the signaling effects of semaglutide in neurons.
ScienceDaily files mainly under science. We currently carry 84 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | ScienceDaily |
| Canonical URL | https://www.sciencedaily.com/releases/2026/05/260525000453.htm |
| Publication time | Mon, 25 May 2026 09:39:26 EDT |
| Retrieval time | 2026-05-25T13:42:37.970Z |
| Last seen | 2026-05-25T13:42:37.970Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | l_naJcTKq17F |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Science News from research organizations Scientists discover why Ozempic and Wegovy weight loss eventually plateaus Date: May 25, 2026 Source: NIH/Office of the Director Summary: New NIH research reveals that semaglutide sparks different responses inside appetite-controlling brain cells, offering fresh insight into why GLP-1 weight-loss drugs don’t work the same for everyone. Scientists also found a possible way to extend the drugs’ effects, potentially helping patients push past weight-loss plateaus. Share: Facebook Twitter Pinterest LinkedIN Email FULL STORY Scientists may have discovered why GLP-1 weight-loss drugs eventually plateau — and how to make them work longer.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at ScienceDaily.
Discussion
0 commentsMore from ScienceDaily
